The New Era of Biologics in Atopic Dermatitis: A Review
Keywords:
atopic dermatitis,, therapy, biological, dupilumabAbstract
Atopic dermatitis (AD) is a prevalent inflammatory skin disorder affecting all ages and ethnic groups. The age-dependent varying appearance and extent of pruritic lesions are accompanied by distinct individual suffering, highlighting the importance of effective treatment options. Over the past years, systemic drugs have considerably extended therapeutic approaches of patients with moderate to severe AD, in particular, new biologics, most notably dupilumab has appeared as major breakthrough. In addition to monoclonal blockade of IL-4 and IL-13 pathway, more cytokines have been found to play a substantial role in AD pathogenesis, presenting potential targets for new therapy options.
References
Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33(7):1331-1340. DOI: 10.1111/jdv.15634.PMID: 31002197.
Zink AGS, Arents B, Fink-Wagner A, Seitz IA, Mensing U, Wettemann N, de Carlo G, Ring J. Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries. Acta Derm Venereol. 2019;99(3): 263-267. DOI: 10.2340/00015555-3102. PMID: 30521060.
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020; 396(10247):345-360. DOI: 10.1016/s0140-6736(20)31286-1.
Paternoster L, Standl M, Waage J, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015; 47(12): 1449-1456. DOI: 10.1038/ng.3424.
Jungersted JM, Scheer H, Mempel M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010;65(7):911-8. DOI: 10.1111/j.1398-9995.2010.02326.x. PMID: 20132155.
Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship. Trends Microbiol. 2018;26(6):484-497. DOI: 10.1016/j.tim.2017.11.008.PMID: 29233606.
Ho IC, Miaw SC. Regulation of IL-4 Expression in Immunity and Diseases. Adv Exp Med Biol.2016; 941: 31-77. DOI: 10.1007/978-94-024-0921-5_3. PMID: 27734408.
Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nature Reviews Drug Discovery. 2016;15(1):35-50. DOI: 10.1038/nrd4624.PMID: 26471366.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014; 371(2):130-9. DOI: 10.1056/NEJMoa1314768. PMID: 25006719.
Wenzel S, Ford L, Pearlman D, et al. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. New England Journal of Medicine. 2013;368(26): 2455-2466. DOI: 10.1056/NEJMoa1304048. PMID: 23688323.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine. 2016;375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. PMID: 27690741.
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1): 44-56. DOI: 10.1001/jamadermatol.2019.3336. PMID: 31693077. PMCID: PMC6865265.
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293. DOI: 10.1016/j.jaad.2020.06.054. PMID: 32574587.
Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021;35(2):464-475. DOI: 10.1111/jdv.16928. PMID: 32893393. PMCID: PMC7894166.
Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129(3): 742-51. DOI: 10.1038/jid.2008.295. PMID: 18830273. PMCID :PMC4356214.
Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11): 459-64. DOI: 10.1007/s00403-004-0455-6. PMID: 15014952.
Li R, Hadi S, Guttman-Yassky E. Current and emerging biologic and small molecule therapies for atopic dermatitis. Expert Opin Biol Ther. 2019;19(4):367-380. DOI: 10.1080/14712598.2019.1573422. PMID: 30672355.
Worm M, Francuzik W, Kraft M, Alexiou A. Modern therapies in atopic dermatitis: biologics and small molecule drugs. J Dtsch Dermatol Ges. 2020;18(10): 1085-1092. DOI: 10.1111/ddg.14175.
Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 184(3): 437-449. DOI: 10.1111/bjd.19574. PMID: 33000465. PMCID: PMC7986411.
Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020;156(4):411-420. DOI: 10.1001/jamadermatol.2020.0079. PMID: 32101256. PMCID: PMC7142380.
Nobbe S, Dziunycz P, Mühleisen B, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012; 92(1):24-8. DOI: 10.2340/00015555-1191. PMID: 22041865.
Takamori A, Nambu A, Sato K, et al. IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity. Scientific Reports. 2018; 8(1):6639. DOI: 10.1038/s41598-018-25094-4. PMID: 29703903. PMCID: PMC5923199.
Grimstad O, Sawanobori Y, Vestergaard C, Bilsborough J, Olsen UB, Grønhøj-Larsen C, Matsushima K. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol.2009; 18(1):35-43. DOI: 10.1111/j.1600-0625.2008.00766.x. PMID: 19054054.
Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med. 2017;376(9):826-835. DOI: 10.1056/NEJMoa1606490. PMID: 28249150.
Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174(2): 296-304. DOI: 10.1111/bjd.14207. PMID: 26409172.
Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482-493.e7. DOI: 10.1016/j.jaci.2018.11.053. PMID :30738171.
Nakagawa H, Iizuka H, Nemoto O, Shimabe M, Furukawa Y, Kikuta N, Ootaki K. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci. 2020;99(2):82-89. DOI: 10.1016/j.jdermsci.2020.06.005. PMID: 32651105.
Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, van der Merwe R. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol. 2019; 80(4): 1013-1021. DOI: 10.1016/j.jaad.2018.11.059. PMID: 30550828.
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90. DOI: 10.1016/j.immuni.2005.09.015. PMID: 16286016.
Murakami-Satsutani N, Ito T, Nakanishi T, et al. IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. Allergol Int. 2014;63(3):443-55. DOI: 10.2332/allergolint.13-OA-0672.
Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484-90. DOI: 10.1016/j.jaci.2008.04.005. PMID: 18539196. PMCID: PMC2821937.
Peng G, Mu Z, Cui L, Liu P, Wang Y, Wu W, Han X. Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene. Inflammation. 2018;41(1):154-163. DOI: 10.1007/s10753-017-0673-7. PMID: 28952069.
Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515). DOI: 10.1126/scitranslmed.aax2945. PMID: 31645451.
Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009;123(6): 1244-52.e2.DOI: 10.1016/j.jaci.2009.03.041. PMID: 19439349. PMCID: PMC2874584.
Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015; 135(2):324-36.DOI: 10.1016/j.jaci.2014.11.015. PMID: 25541257.
Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol.2018;(78) 5: 872-881.e6. DOI: 10.1016/j.jaad.2018.01.016. PMID: 29353025.
Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128(11):2625-2630. DOI: 10.1038/jid.2008.111. PMID: 18432274.
Published
Issue
Section
License
Copyright (c) 2021 Simon Schneider, Linda Li, Alexander Zink
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
